Study summary

Adding marizomib to standard treatment did not extend survival

Marizomib phase 3 · 749 people, phase 3 · Published September 2024, Neuro-Oncology

What was tested

Marizomib, a brain-penetrating proteasome inhibitor, added to radiation and temozolomide for newly diagnosed glioblastoma.

What they found

• Survival was the same with or without marizomib.

What it means

Shows how hard glioblastoma is to improve, and why new approaches (cell therapy, devices) are being tried.